Inostics' Lab Gains CLIA Licensure | GenomeWeb

NEW YORK (GenomeWeb News) – Molecular diagnostics firm Inostics announced today that its clinical laboratory in Baltimore, Md., has received CLIA licensure, allowing it to offer its non-invasive OncoBeam tumor mutation test.

The blood-based test is based on Beaming — or Beads, Emulsions, Amplification, and Magnetics — technology that combines emulsion-based digital PCR with flow cytometry. Inostics said the technology allows for the molecular analysis of tumor DNA shed from primary and metastatic tumors found circulating in a patient's blood.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: certain genes repressed during memory formation, analysis of genomes from single neurons, and more.

NASA plans to test whether DNA sequencing studies can be conducted in microgravity.

Congress passes a continuing resolution to keep the US federal government funded through mid-December.

The Human Genome Project was launched 25 years ago, and at Nature, Francis Collins, James Watson, and Eric Green look back at the lessons learned.